GSP Crop Science Ltd

GSP Crop Science has completed the acquisition of balance 21% equity stake in GSP Intermediates (GIPL), a subsidiary of the company. Consequent to the completion of aforesaid acquisition, the company's shareholding in GIPL has increased to 100% and GIPL has become a wholly-owned subsidiary of the company.

GSP Crop Science announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of GSP Crop Science declined 9.62% to Rs 20.48 crore in the quarter ended March 2026 as against Rs 22.66 crore during the previous quarter ended March 2025. Sales rose 30.68% to Rs 402.47 crore in the quarter ended March 2026 as against Rs 307.99 crore during the previous quarter ended March 2025. For the full year,net profit rose 17.33% to Rs 97.90 crore in the year ended March 2026 as against Rs 83.44 crore during the previous year ended March 2025. Sales rose 17.84% to Rs 1517.11 crore in the year ended March 2026 as against Rs 1287.39 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales402.47307.99 31 1517.111287.39 18 OPM %9.0212.89 -12.2011.68 - PBDT35.2639.22 -10 162.03133.09 22 PBT27.1631.91 -15 131.74109.68 20 NP20.4822.66 -10 97.9083.44 17 Powered by Capital Market - Live

GSP Crop Science will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Revenue from operations declined 2% year-on-year to Rs 270.35 crore for the quarter ended 31 December 2025. The company reported a pre-tax loss of Rs 3.18 crore in Q3 FY26, compared to a pre-tax loss of Rs 11.04 crore in the same quarter last year. Exceptional items during the quarter stood at Rs 4.51 crore. On a nine-month basis, the company's consolidated net profit rose 27.4% to Rs 77.42 crore on a 13.8% increase in total revenue to Rs 1,114.64 crore in 9M FY26 compared to 9M FY25. GSP Crop Science are a research-driven agrochemical company, specializing in the development and manufacturing of insecticides, herbicides, fungicides and plant growth regulators in India. The counter slipped 1.37% to Rs 384.80 on the BSE.

GSP Crop Science will hold a meeting of the Board of Directors of the Company on 11 April 2026.

The stock was listed at Rs 332.30, exhibiting a premium of 3.84% to the issue price. So far, the stock has hit a high of Rs 362.30 and a low of Rs 327.35. On the BSE, over 2.29 lakh shares of the company were traded in the counter so far. GSP Crop Science was subscribed 1.61 times. The issue opened for bidding on 16 March 2026, and it closed on 18 March 2026. The price band of the IPO was fixed between Rs 304 and 320 per share. The Rs 400 crore IPO had comprised a fresh issue of 75,00,000 equity shares aggregating Rs 240 crore and an offer for sale (OFS) of up to 50,00,000 equity shares aggregating Rs 160 crore at the upper price band of Rs 320. Promoters Vilasben Vrajmohan Shah, Bhavesh Vrajmohan, and others had offloaded part of their stake through the OFS. GSP will utilize Rs 170 crore from the net fresh issue proceeds towards repayment of borrowings, with the balance to be used for general corporate purposes. Ahead of the IPO of GSP Crop Science on 13 March 2026, the company raised Rs 120 crore from anchor investors by allotting 37.50 lakh shares at Rs 320 each to 3 anchor investors. GSP Crop Science (GSP) is an agrochemical company engaged in the business of manufacturing insecticides, herbicides, fungicides, and plant growth regulators. It provides crop protection solutions to help farmers increase productivity, offering formulations (active ingredients and additives) and technicals (concentrated active ingredients) for effective pest, weed, and disease control. The company offers a diverse portfolio of in-house manufactured agrochemicals, providing crop protection solutions through the development, manufacturing, supply, and distribution of formulations and technicals to meet customer needs. For the six months ended 30 September 2026, the company earned 82.9% of its revenues from the sale of generic products and the balance of 17.1% from the sale of patented products. During the six months ended 30 September 2025, the firm recorded a consolidated net profit of Rs 82.78 crore and sales of Rs 844.29 crore.Powered by Capital Market - Live